Having determined that 17D efficacy is mediated by CD8 T‐cell responses, 17D intratumoral injections were predicted to augment immune cell infiltrates and induce parallel changes in tumor‐draining lymph nodes (TDLN) toward which the virus and antigen‐presenting cells ought to be drained. This evidence concerns the gene CD8A and neoplasm.